drugset / Trial / NCT02954198

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

NCT02954198

Completed 40 enrolled Medical University of South Carolina
RandomizedParallel-groupOpen-labelTreatment

Summary

With the availability of well-studied once-daily formulations of tacrolimus, the ability to achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may finally be achievable and have the potential to optimize immunosuppression safety and efficacy in kidney transplantation.

Timeline

Start
2016-12-01
Primary completion
2018-12-27
Completion
2018-12-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Everolimus Small molecule
Comparator Mycophenolate Mofetil Small molecule 1 g
Comparator Tacrolimus Small molecule
Comparator Prednisone Other / unclassified 5 mg